Adjuvant Chemotherapy — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	19	11	20	44	—	—	1999-09
Malignant Rectal Neoplasm	Phase4	Phase 4	2	2	1	5	—	—	Jun 6, 2006
Malignant Colon Neoplasm	Phase3	Phase 3	4	1	2	6	—	—	2014-10
Malignant Gastric Neoplasm	Phase3	Phase 3	2	1	1	5	—	—	2013-06
Malignant Lung Neoplasm	Phase3	Phase 3	2	0	1	3	—	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Deleterious Mutation1
Adjuvant Chemotherapy

Clinical trials

Trials with this intervention (50)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 50 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01817192	Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)	active not recruiting	N/A	420	Razor GenomicsINDUSTRY	3	Sep 11, 2026	clinicaltrials
NCT02676349	Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)